Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96
   PubMed Web of Science ®Google Scholar
• George DJ, Kaelin WG Jr. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med 2003;349:419-25
   PubMed Web of Science ®Google Scholar
• Young AC, Craven RA, Cohen D, Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res 2009;15(24):7582-92
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Murphy BA, Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96
   PubMed Web of Science ®Google Scholar
• Mekhail TM, Abou-Jawde RM, BouMerhi G, Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832-40
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-8
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, Bukowski RM, Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-24
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a Randomized Phase III Trial. J Clin Oncol 2010;28:1061-8
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-53
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-33
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE, Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422-30
   PubMed Web of Science ®Google Scholar
• Hutson TE, Davis ID, Machiels JH, Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010;27:475-80
   Web of Science ®Google Scholar
• Escudier B, Szczylik C, Hutson TE, Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1280-7
   PubMed Web of Science ®Google Scholar
• Mills EJ, Rachlis B, O'Regan C, Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer 2009;9:34-40
   PubMed Web of Science ®Google Scholar
• Thompson Coon JS, Liu Z, Hoyle M, Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. Br J Cancer 2009;101:238-43
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90
   PubMed Web of Science ®Google Scholar
• Escudier B, Bellmunt J, Negrier S, Phase III Trial of bevacizumab plus interferon Alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. Published ahead of print on 5 April 2010. Available from: http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2009.26.7849
   Google Scholar
• Melichar B, Koralewski P, Ravaud A, First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008;19:1470-8
   PubMed Web of Science ®Google Scholar
• Bevacizumab + IFN alpha. Inpharma 2008;1(1620):27
   Google Scholar
• Rini BI, Halabi S, Rosenberg JE, Phase III Trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. Published Ahead of Print on 5 April 2010. Available from: http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2009.26.5561
   Google Scholar
• Castaneda CA, Gomez HL. Pazopanib: an antiangiogenic drug in perspective. Future Oncol 2009;5(9):1335-48
   PubMed Web of Science ®Google Scholar
• Dutcher JP, de Souza P, McDermott D, Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009;26:202-10
   PubMed Web of Science ®Google Scholar
• Logan T, McDermott DF, Dutcher JP, Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features. J Clin Oncol 2008;26(20 Suppl): abstract 5050
   Google Scholar
• Wyeth Pharmeceuticals, data on file
   Google Scholar
• Interleukin-2. Available from: www.accessdata.fda.gov/scripts/cder/drugsatfda (5/5/92)
   Google Scholar
• Fyfe G, Fisher RI, Rosenberg SA, Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;139:688-96
   Google Scholar
• Yang JC, Sherry RM, Steinberg SM, Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127-35
   PubMed Web of Science ®Google Scholar
• McDermott DF, Regan MM, Clark JI, Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-41
   PubMed Web of Science ®Google Scholar
• McDermott D, Ghebremichael M, Signoretti S, The high-dose aldesleukin (HD IL-2) “Select” trial in patients with metastatic renal cell carcinoma (mRCC): preliminary assessment of clinical benefit. ASCO Genitourinary cancer symposium, JCO, San Francisco; 2010
   Google Scholar
• Motzer RJ, Bacik J, Mariani T, Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002;20:2376-81
   PubMed Web of Science ®Google Scholar
• Quesada JR, Swanson DA, Trindale A, Renal cell carcinoma antitumor effects of leukocyte interferon. Cancer Res 1983;43:940-7
   PubMed Web of Science ®Google Scholar
• Bukowski RM, Novick AC. Clinical practice guidelines: renal cell carcinoma. Cleve Clin J Med 1997;64:S1-48
   Web of Science ®Google Scholar
• Pyrhonen S, Salminen E, Ruuru M, Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17:2859-67
   PubMed Web of Science ®Google Scholar
• Medical Research Council Renal Cancer Collaborators. Interferon alphaand survival in metastatic renal cell carcinoma: early results of randomized trial. Lancet 1999;353:14-17
   PubMed Web of Science ®Google Scholar
• Gore ME. Interferon-alpha (IFN), interleukin-2 (IL-2), and 5-fluorouracil (5-FU) vs IFN alone in patients with metastatic renal cell carcinoma (mRCC): results of the randomized MRC/EORTC RE043 trial (abstract 5039). J Clin Oncol 2008;26(15 Suppl):259s
   Web of Science ®Google Scholar
• Motzer RJ, Murphy BA, Bacik J, Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18:2972-80
   PubMed Web of Science ®Google Scholar
• Negrier S, Escudier B, Lasset C, Recombinant human interleukin-2, recombinant interferon alfa-2a, or both in metastatic renal cell carcinoma. Groupe Francaise d'Immunotherapie. N Engl J Med 1998;338:1272-8
   PubMed Web of Science ®Google Scholar
• Flannigan RC, Salmon E, Blumenstein BA, Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal cell carcinoma. N Engl J Med 2001;345:1655-9
   PubMed Web of Science ®Google Scholar
• Coppin C, Porzsolt F, Kumpf J, Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2000;110:CD001425
   Google Scholar
• Negrier S, Perol D, Ravaud A, Medroxyprogesterone, interferon alfa-2a, Interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 2007;110:2468-77
   PubMed Web of Science ®Google Scholar
• Naito S, Yamamoto N, Takayama T, Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol 2010;57:317-26
   PubMed Web of Science ®Google Scholar
• Comparz. Phase 3 trial of sunitinib vs pazopanib. ClinicalTrial.gov; NCT00720941
   Google Scholar
• Record 2. Phase 3 trial of bevacizumab + everolimus vs bevacizumab + IFN alpha. ClinicalTrial.gov; NCT00719264
   Google Scholar
• Record 3. Phase 2 trial of sunitinib vs everolimus. ClinicalTrial.gov; NCT00903175
   Google Scholar
• Intoract. Phase 3 trial comparing bevacizumab + IFN alpha to bevacizumab + temsirolimus. ClinicalTrial.gov; NCT00631371
   Google Scholar
• Bukowski RM, Kabbinavar FF, Figlin RA, Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25:4536-41
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34
   PubMed Web of Science ®Google Scholar
• Sorafenib. Available from: www.accessdata.fda.gov/scripts/cder/drugsatfda (12/20/05)
   Google Scholar
• Sorafenib. Available from: www.medscape.com/viewarticle/541998 (2006)
   Google Scholar
• Sunitinib. Available from: www.accessdata.fda.gov/scripts/cder/drugsatfda (1/26/06)
   Google Scholar
• Sunitinib. Available from: www.emea.europa.eu/humandocs/PDFs/EPAR/sutent/068706en1.pdf (2007)
   Google Scholar
• Bevacizumab + IFN alpha. Available from: www.accessdata.fda.gov/scripts/cder/drugsatfda (7/31/09)
   Google Scholar
• Pazopanib. Available from: www.accessdata.fda.gov/scripts/cder/drugsatfda (10/19/09)
   Google Scholar
• Temsirolimus. Available from: www.accessdata.fda.gov/scripts/cder/drugsatfda (5/30/07)
   Google Scholar
• Temsirolimus. Inpharma 2007;1(1616):27
   Google Scholar
• Everolimus. Available from: www.accessdata.fda.gov/scripts/cder/drugsatfda (3/30/09)
   Google Scholar